-
HRQoL data analysis of KEYNOTE-426: pembrolizumab combined with axitinib vs. sunitinib in the treatment of advanced renal cell carcinoma
Time of Update: 2023-01-07
Conclusion of the study Overall, pembrolizumab + axitinib delayed disease progression and prolonged survival compared with sunitinib, and no significant difference in HRQoL outcomes was found between the two regimens, and these data further support the use of pembrolizumab + axitinib as the standard of care for first-line treatment in patients with RCC.
-
Research Frontier ARAMIS trial results update: treatment of nmCRPC patients, darolutamide can be expected in the future!
Time of Update: 2023-01-07
GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
-
Professor Ma Limin "Medicine" road is long, and the waves are surging
Time of Update: 2023-01-07
Yimaitong edited and sorted, please do not reprint without authorization. "An "Medicine" Leye" is a humanistic case collection project cooperated by Beijing Chen Jumei Public Welfare Foundation and Yi
-
Research Frontiers Does lowering the starting dose of lenvatinib affect the efficacy of advanced RCC?
Time of Update: 2023-01-07
Guide Based on the results of Study 205, lenvatinib (18 mg) in combination with everolimus (5 mg) has been approved in Europe and the United States for the second-line treatment of patients with advanced renal cell carcinoma (RCC) who have progressed after a previous antiangiogenic therapy 。 In order to reduce the occurrence of adverse events (TEAEs) during treatment, the US research team conducted a large-scale lenvatinib dose optimization study and published the results in European Urology.
-
Prostatic hyperplasia patients for several years of "male" words, 10 minutes can be solved? Results of a multicenter study of the minimally invasive therapy Rezum announced
Time of Update: 2023-01-07
Recently, an article published by Prostate Cancer Prostatic Dis announced the urinary and sexual function outcomes of BPH patients after minimally invasive therapy Rezum.
Recently, an article published by Prostate Cancer Prostatic Dis announced the urinary and sexual function outcomes of BPH patients after minimally invasive therapy Rezum.
-
Research Frontiers Does Age Affect the Prognosis of RNU in UTUC Patients?
Time of Update: 2023-01-06
Figure 1 OS data of patients under different groupsBased on the results of multivariate COX regression analysis (Table 2), the investigators found no significant correlation between sex, smoking history, ASA grade, CCI, and RNU and overall survival, and the performance trend was consistent between the two age groups.
-
Clinical essentials Overview of key points in the diagnosis and treatment of varicocele
Time of Update: 2023-01-06
Flavonoids: can improve the pain symptoms caused by clinical varicocele and delay the progression of subclinical varicocele to clinical typeOther medications that improve symptomsFor patients with local pain and discomfort, first-line treatment includes nonsteroidal anti-inflammatory drugs, which can relieve to some extent the pain, discomfort and other related symptoms of the scrotum and its contents caused by varicocele.
-
Research Frontier ARAMIS Test Results Update: For Non-metastatic Castration-Resistant Prostate Cancer, Darolutamide Can Be Expected in the Future!
Time of Update: 2023-01-06
END GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
END GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
-
The 16th Filipino Salon invites you to share the academic feast
Time of Update: 2023-01-06
Friends, new wonderful. On November 5, 2022, the 16th "Filipino Salon" hosted by Ipsen China was successfully held online. This conference invited several authoritative experts to gather online, close
-
The new treatment of ED is popular in beauty salons, can it work?
Time of Update: 2023-01-06
? Low-intensity extracorporeal shock wave is a "regenerative therapy" for erectile dysfunction (ED) that has spread throughout Europe and the United States in recent years, and is said to restore the youthfulness of blood vessels in key areas.
-
Research Frontiers Did you know? What are the effects of miraperion and solifenacin in women with OAB?
Time of Update: 2023-01-06
GuideThe effects of miraberon and solifenacin on autonomic function and peripheral arterial disease in women with overactive bladder syndrome (OAB) are unclear and worth exploring.
GuideThe effects of miraberon and solifenacin on autonomic function and peripheral arterial disease in women with overactive bladder syndrome (OAB) are unclear and worth exploring.
-
Research Frontiers Did you know? What are the effects of miraperion and solifenacin in women with OAB?
Time of Update: 2023-01-06
GuideThe effects of miraberon and solifenacin on autonomic function and peripheral arterial disease in women with overactive bladder syndrome (OAB) are unclear and worth exploring.
GuideThe effects of miraberon and solifenacin on autonomic function and peripheral arterial disease in women with overactive bladder syndrome (OAB) are unclear and worth exploring.
-
Research Frontiers Does Age Affect the Prognosis of RNU in UTUC Patients?
Time of Update: 2023-01-06
Figure 1 OS data of patients under different groupsBased on the results of multivariate COX regression analysis (Table 2), the investigators found no significant correlation between sex, smoking history, ASA grade, CCI, and RNU and overall survival, and the performance trend was consistent between the two age groups.
-
Science Bulletin CCIN mutations cause teratospermia and male infertility
Time of Update: 2023-01-06
CCIN mutation leading to sperm head malformation and male infertilityStarting from clinical male infertility cases, this study identifies new pathogenic gene mutations and elucidates the relevant mechanisms through basic research, and explores corresponding treatment strategies, providing important clues for genetic counseling and assisted reproduction treatment in clinical male infertility cases.
-
2022 CSCO | Professor Sheng Xinan: The ice-breaking operation is underway, and the era of immunoprecision treatment for urothelial carcinoma will finally come
Time of Update: 2023-01-06
Professor Sheng Xinan:In terms of postoperative adjuvant treatment for urothelial carcinoma, the 2022 version of the CSCO guidelines for urothelial carcinoma has basically no major changes compared with the 2021 version, and we have adjusted and sorted out the adjuvant treatment part of upper urothelial carcinoma (UTUC), but the essence of the guidelines remains unchanged.
-
Research Frontiers Biochemical recurrence time as a prognostic indicator for salvage radiotherapy in prostate cancer patients
Time of Update: 2023-01-06
Therefore, the investigators hypothesized that sBCR in patients over a short period of time was associated with poor tumor control, and validated it as a predictor of prostate-specific death in patients who underwent sRT after failed radical prostatectomy.
-
Clinical essentials Overview of key points in the diagnosis and treatment of varicocele
Time of Update: 2023-01-06
Flavonoids: can improve the pain symptoms caused by clinical varicocele and delay the progression of subclinical varicocele to clinical typeOther medications that improve symptomsFor patients with local pain and discomfort, first-line treatment includes nonsteroidal anti-inflammatory drugs, which can relieve to some extent the pain, discomfort and other related symptoms of the scrotum and its contents caused by varicocele.
-
How can "evidence-based medicine" improve symptoms related to ureteral stent tubes? Complete ureteral stent placement may be a better solution
Time of Update: 2023-01-06
Study designBased on the Systematic Review and Meta-Analysis Priority Report Entry (PRISMA) statement, the investigators used the following subject terms ((complete intraureteral stent) OR (suture stent)) AND (symptom OR pain) AND (randomized OR randomised) for PubMed, Embase, Web of A systematic and comprehensive search of relevant English literature published before December 2021 in the three databases of Science was conducted.
-
Research Frontier ARAMIS Test Results Update: For Non-metastatic Castration-Resistant Prostate Cancer, Darolutamide Can Be Expected in the Future!
Time of Update: 2023-01-06
END GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
END GuidePatients with prostate-specific antigen doubling time (PSADT) ≤ 10 months of non-metastatic castration-resistant prostate cancer (nmCRPC) are at high risk of disease progression and metastasis.
-
The new treatment of ED is popular in beauty salons, can it work?
Time of Update: 2023-01-06
? Low-intensity extracorporeal shock wave is a "regenerative therapy" for erectile dysfunction (ED) that has spread throughout Europe and the United States in recent years, and is said to restore the youthfulness of blood vessels in key areas.
